When elimination leaves patients behind: clinical, serologic and molecular evidence of a human African trypanosomiasis case highlighting diagnostic, surveillance and treatment gaps in Nigeria

BACKGROUND: Despite substantial progress toward elimination, human African trypanosomiasis (HAT) remains vulnerable to under-recognition in low-surveillance settings. Nigeria, historically endemic for HAT, has reported very few recent cases, which raises questions about whether declining incidence reflects true interruption of transmission or limitations in surveillance and diagnostic systems. Here, we report a case that illustrates the unique challenges of case detection and surveillance, confirmation and treatment in Nigeria, which resulted in poor patient outcomes and ongoing transmission that may hinder sustainable HAT elimination. CASE PRESENTATION: A 17-year-old male from Imo State, Nigeria, first developed recurrent seizures in 2020 at the age of 12 and received treatment for epilepsy for approximately 4 years before progressive neurological deterioration prompted further investigations for HAT. Serological and molecular testing supported infection with Trypanosoma brucei, and cerebrospinal fluid findings were consistent with second-stage HAT. Tested family members also showed positive serological and molecular results, suggesting possible undetected transmission within the household. Despite the cumulative clinical, serologic and molecular evidence, treatment was not initiated owing to prevailing operational practices in the country. Patient's symptoms remain unabated with continued anti-epilepsy treatment and no access to HAT medications. CONCLUSIONS: This case demonstrates how prolonged clinical misdiagnosis, gaps in surveillance, and barriers to accessing treatment can delay recognition and management of HAT in low-prevalence settings, especially in the absence of parasitological confirmation. It also highlights broader challenges facing elimination programmes, illustrating how the gap between international diagnostic/treatment guidelines and operational practice affects patient care. The detection of infection markers among family members further raises concern about under-recognized transmissions in Nigeria. Strengthening clinician awareness, enhancing surveillance systems, conducting family-based case investigations, and ensuring timely access to adequate diagnosis and treatment will be essential for achieving equitable HAT elimination.

Authors

Institutions

Publication Details

Journal
Infectious Diseases of Poverty
Published
2026-11-18
DOI
https://doi.org/10.1186/s40249-026-01522-w
Primary Topic
Trypanosoma species research and implications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

When elimination leaves patients behind: clinical, serologic and molecular evidence of a human African trypanosomiasis case highlighting diagnostic, surveillance and treatment gaps in Nigeria

Chinwe Uzoma Chukwudi, Oluwamayowa Opara, Michael Grigg, Jonadab C. Chinwendu et al.
1 links
Infectious Diseases of Poverty
Trypanosoma species research and implications
article

When elimination leaves patients behind: clinical, serologic and molecular evidence of a human African trypanosomiasis case highlighting diagnostic, surveillance and treatment gaps in Nigeria

Chinwe Uzoma Chukwudi, Oluwamayowa Opara, Michael Grigg, Jonadab C. Chinwendu, Babatunde Joshua, Silvanus Anika, Edward Nwanegbo, Omolara Adenekan
article en

Abstract

BACKGROUND: Despite substantial progress toward elimination, human African trypanosomiasis (HAT) remains vulnerable to under-recognition in low-surveillance settings. Nigeria, historically endemic for HAT, has reported very few recent cases, which raises questions about whether declining incidence reflects true interruption of transmission or limitations in surveillance and diagnostic systems. Here, we report a case that illustrates the unique challenges of case detection and surveillance, confirmation and treatment in Nigeria, which resulted in poor patient outcomes and ongoing transmission that may hinder sustainable HAT elimination. CASE PRESENTATION: A 17-year-old male from Imo State, Nigeria, first developed recurrent seizures in 2020 at the age of 12 and received treatment for epilepsy for approximately 4 years before progressive neurological deterioration prompted further investigations for HAT. Serological and molecular testing supported infection with Trypanosoma brucei, and cerebrospinal fluid findings were consistent with second-stage HAT. Tested family members also showed positive serological and molecular results, suggesting possible undetected transmission within the household. Despite the cumulative clinical, serologic and molecular evidence, treatment was not initiated owing to prevailing operational practices in the country. Patient's symptoms remain unabated with continued anti-epilepsy treatment and no access to HAT medications. CONCLUSIONS: This case demonstrates how prolonged clinical misdiagnosis, gaps in surveillance, and barriers to accessing treatment can delay recognition and management of HAT in low-prevalence settings, especially in the absence of parasitological confirmation. It also highlights broader challenges facing elimination programmes, illustrating how the gap between international diagnostic/treatment guidelines and operational practice affects patient care. The detection of infection markers among family members further raises concern about under-recognized transmissions in Nigeria. Strengthening clinician awareness, enhancing surveillance systems, conducting family-based case investigations, and ensuring timely access to adequate diagnosis and treatment will be essential for achieving equitable HAT elimination.

Infectious Diseases of PovertyVol. 15(1)
University of Nigeria (NG), National Institutes of Health (US), Imo State University (NG), National Institute of Allergy and Infectious Diseases (US), Imo State University Teaching Hospital (NG), University of Houston (US), Webster University (US)
Bill and Melinda Gates Foundation, African Academy of Sciences, National Institutes of Health
Good health and well-being
Trypanosoma species research and implications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon